Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study
Kwang-Hee Shin,1 Ji-Young Jeon,2 Kyungho Jang,2 Tae-Eun Kim,3 Min-Gul Kim2,4 1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea; 2Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/dose-proportional-pharmacokinetic-properties-of-gla5pr-glars-nf1-contr-peer-reviewed-article-DDDT |
id |
doaj-561dd9f87c9f475eaf19a78448b8533f |
---|---|
record_format |
Article |
spelling |
doaj-561dd9f87c9f475eaf19a78448b8533f2020-11-25T02:30:51ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-10-01Volume 123449345741371Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel studyShin KHJeon JYJang KKim TEKim MGKwang-Hee Shin,1 Ji-Young Jeon,2 Kyungho Jang,2 Tae-Eun Kim,3 Min-Gul Kim2,4 1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea; 2Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea; 3Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul, Republic of Korea; 4Department of Pharmacology, School of Medicine, Chonbuk National University, Jeonju, Republic of Korea Purpose: The aim of this study was to evaluate the dose-proportional pharmacokinetic characteristics of pregabalin following the administration of GLA5PR GLARS-NF1 tablets (150, 300, 450, and 600 mg) in the fed state.Subjects and methods: An open-label, randomized, single-dose, parallel study was conducted in 40 eligible subjects who were randomly assigned to receive a single 150, 300, 450, or 600 mg dose of GLA5PR GLARS-NF1. Serial blood samples were collected before and after dosing for 36 hours, and plasma concentrations were determined using liquid chromatography-tandem mass spectrometry. Safety profiles were evaluated throughout the study (trial registration number: NCT02327000).Results: Thirty-seven subjects completed the studies. The area under the plasma concentration-time curve up to the last measurable concentration of pregabalin exhibited dose proportionality following administration of GLA5PR GLARS-NF1 tablets from 150 to 600 mg while its maximum plasma concentration showed dose proportionality at a dose range of 150–450 mg. The safety evaluations showed no clinically significant finding after administration of GLA5PR GLARS-NF1 tablets (150, 300, 450, and 600 mg) in the fed state.Conclusions: The dose-proportional properties of GLA5PR GLARS-NF1 150–450 mg tablets were determined. Keywords: gamma-aminobutyric acid analog, GABA analog, maximum concentration, safety evaluation, Koreanhttps://www.dovepress.com/dose-proportional-pharmacokinetic-properties-of-gla5pr-glars-nf1-contr-peer-reviewed-article-DDDTGamma-aminobutyric acid (GABA) analogmaximum concentrationsafety evaluation Korean |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shin KH Jeon JY Jang K Kim TE Kim MG |
spellingShingle |
Shin KH Jeon JY Jang K Kim TE Kim MG Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study Drug Design, Development and Therapy Gamma-aminobutyric acid (GABA) analog maximum concentration safety evaluation Korean |
author_facet |
Shin KH Jeon JY Jang K Kim TE Kim MG |
author_sort |
Shin KH |
title |
Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study |
title_short |
Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study |
title_full |
Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study |
title_fullStr |
Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study |
title_full_unstemmed |
Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study |
title_sort |
dose-proportional pharmacokinetic properties of gla5pr glars-nf1 controlled-release pregabalin in healthy korean volunteers: a randomized, open, single-dose, parallel study |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2018-10-01 |
description |
Kwang-Hee Shin,1 Ji-Young Jeon,2 Kyungho Jang,2 Tae-Eun Kim,3 Min-Gul Kim2,4 1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea; 2Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea; 3Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul, Republic of Korea; 4Department of Pharmacology, School of Medicine, Chonbuk National University, Jeonju, Republic of Korea Purpose: The aim of this study was to evaluate the dose-proportional pharmacokinetic characteristics of pregabalin following the administration of GLA5PR GLARS-NF1 tablets (150, 300, 450, and 600 mg) in the fed state.Subjects and methods: An open-label, randomized, single-dose, parallel study was conducted in 40 eligible subjects who were randomly assigned to receive a single 150, 300, 450, or 600 mg dose of GLA5PR GLARS-NF1. Serial blood samples were collected before and after dosing for 36 hours, and plasma concentrations were determined using liquid chromatography-tandem mass spectrometry. Safety profiles were evaluated throughout the study (trial registration number: NCT02327000).Results: Thirty-seven subjects completed the studies. The area under the plasma concentration-time curve up to the last measurable concentration of pregabalin exhibited dose proportionality following administration of GLA5PR GLARS-NF1 tablets from 150 to 600 mg while its maximum plasma concentration showed dose proportionality at a dose range of 150–450 mg. The safety evaluations showed no clinically significant finding after administration of GLA5PR GLARS-NF1 tablets (150, 300, 450, and 600 mg) in the fed state.Conclusions: The dose-proportional properties of GLA5PR GLARS-NF1 150–450 mg tablets were determined. Keywords: gamma-aminobutyric acid analog, GABA analog, maximum concentration, safety evaluation, Korean |
topic |
Gamma-aminobutyric acid (GABA) analog maximum concentration safety evaluation Korean |
url |
https://www.dovepress.com/dose-proportional-pharmacokinetic-properties-of-gla5pr-glars-nf1-contr-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT shinkh doseproportionalpharmacokineticpropertiesofgla5prglarsnf1controlledreleasepregabalininhealthykoreanvolunteersarandomizedopensingledoseparallelstudy AT jeonjy doseproportionalpharmacokineticpropertiesofgla5prglarsnf1controlledreleasepregabalininhealthykoreanvolunteersarandomizedopensingledoseparallelstudy AT jangk doseproportionalpharmacokineticpropertiesofgla5prglarsnf1controlledreleasepregabalininhealthykoreanvolunteersarandomizedopensingledoseparallelstudy AT kimte doseproportionalpharmacokineticpropertiesofgla5prglarsnf1controlledreleasepregabalininhealthykoreanvolunteersarandomizedopensingledoseparallelstudy AT kimmg doseproportionalpharmacokineticpropertiesofgla5prglarsnf1controlledreleasepregabalininhealthykoreanvolunteersarandomizedopensingledoseparallelstudy |
_version_ |
1724827428979736576 |